Research programme: HDAC6 inhibitors - Celgene

Drug Profile

Research programme: HDAC6 inhibitors - Celgene

Alternative Names: ACY 1083; ACY-738

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer Acetylon Pharmaceuticals; Celgene Corporation
  • Class Small molecules
  • Mechanism of Action HDAC6 protein inhibitors; Histone deacetylase inhibitors; Interleukin 10 inhibitors; Programmed cell death 1 ligand 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Charcot-Marie-Tooth disease; Chronic lymphocytic leukaemia; Depressive disorders; Diabetes mellitus; Neurological disorders; Stroke
  • No development reported Autoimmune disorders; Haematological malignancies

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO)
  • 01 Apr 2016 Preclinical trials in Chronic lymphocytic leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top